Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Neurocrine Biosciences NBIX in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 7 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 4 | 2 | 1 | 0 | 0 |
| 2M Ago | 4 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $152.0, a high estimate of $185.00, and a low estimate of $115.00. Highlighting a 1.89% decrease, the current average has fallen from the previous average price target of $154.93.
Diving into Analyst Ratings: An In-Depth Exploration
The perception of Neurocrine Biosciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Maintains | Outperform | $145.00 | $145.00 |
| David Amsellem | Piper Sandler | Lowers | Overweight | $154.00 | $160.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $145.00 | $137.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $165.00 | $155.00 |
| Evan Seigerman | BMO Capital | Raises | Market Perform | $115.00 | $96.00 |
| Ashwani Verma | UBS | Raises | Buy | $152.00 | $137.00 |
| Sumant Kulkarni | Canaccord Genuity | Raises | Buy | $160.00 | $158.00 |
| Ami Fadia | Needham | Raises | Buy | $139.00 | $138.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $158.00 | $163.00 |
| Cory Kasimov | Evercore ISI Group | Lowers | Outperform | $185.00 | $190.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $168.00 | $185.00 |
| Ami Fadia | Needham | Announces | Buy | $138.00 | - |
| Brian Abrahams | RBC Capital | Lowers | Outperform | $137.00 | $138.00 |
| Ashwani Verma | UBS | Lowers | Buy | $137.00 | $154.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $184.00 | $183.00 |
| Jeffrey Hung | Morgan Stanley | Lowers | Overweight | $150.00 | $185.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Neurocrine Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
Discovering Neurocrine Biosciences: A Closer Look
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
A Deep Dive into Neurocrine Biosciences's Financials
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 11.12%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Neurocrine Biosciences's net margin is impressive, surpassing industry averages. With a net margin of 1.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 0.31%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
